Nomura Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Nomura Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,000	Closed	-$378K	–	894
2015 Q2	$378K	Sell	1,000 -2,333	-70%	-$927K	0.01%	836
2015 Q1	$1.39M	Buy	3,333 +1,333	+67%	+$477K	0.02%	501
2014 Q4	$545K	Buy	+2,000	New	+$497K	0.01%	784
2014 Q1	–	Sell	-1,333	Closed	-$484K	–	878
2013 Q4	$484K	Sell	1,333 -334	-20%	-$129K	0.01%	769
2013 Q3	$886K	Sell	1,667 -333	-17%	-$114K	0.02%	586
2013 Q2	$468K	Buy	+2,000	New	+$394K	0.01%	753

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nomura Asset Management's CLDX Position: Q3 2015 in Review

Nomura Asset Management sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 1,000 shares — an estimated $378K sold.

Nomura Asset Management first reported a position in CLDX in Q2 2013 and held it in 6 quarters. The position peaked at $1.39M in Q1 2015. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

Nomura Asset Management reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
Nomura Asset Management sold 1,000 Celldex Therapeutics shares in Q3 2015, an estimated $378K.
Nomura Asset Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 6 quarters.
Nomura Asset Management's Celldex Therapeutics position peaked at $1.39M in Q1 2015.
162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on Nomura Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.